Notice of Intent to Sole Source Oncotype Cancer Testing Contract Award

The US Department of Defense (DoD) intends to award a sole source contract to Genomic Health, Inc. for Oncotype Dx Cancer testing. This notice is not a request for competitive proposals, and no solicitation document exists for the requirement. The requirement is for Oncotype Dx Cancer testing, which ensures that clinical guidelines and recommendations for patients with colon, prostate, and breast cancer are met.

Key Takeaways:

• The DoD intends to award a sole source contract to Genomic Health, Inc. for Oncotype Dx Cancer testing, valued at an undisclosed amount.
• The requirement is for Oncotype Dx Cancer testing, which ensures that clinical guidelines and recommendations for patients with colon, prostate, and breast cancer are met.
• The contract will be awarded to Genomic Health, Inc. due to the company being the only source available to meet the Government's needs.
• The capability statement is due by 10:00 am Pacific Time, March 4, 2021, and shall be submitted by email ONLY as a Microsoft Word or Adobe PDF to jessica.beck.9@us.af.mil.
• The NAICS code number for this requirement is 621511.
• The opportunity is classified as a sole source procurement, with no set-aside designation.
• The contracting office is located at 5865 SWAAB BLVD NELLIS AFB, NV 89191-7063 USA, with Jessica Beck as the primary point of contact.

Statistics:

• 1 contract award anticipated
• 1 respondent (Genomic Health, Inc.) will be considered for the contract
• 1 capability statement due by 10:00 am Pacific Time, March 4, 2021
• 621511 is the NAICS code number for this requirement
• 0 competitive procurement to be conducted; sole sourc eprocurement
• Contracting office contact: Jessica Beck; email: jessica.beck.9@us.af.mil
• Contracting office address: 5865 SWAAB BLVD NELLIS AFB, NV 89191-7063 USA

Sources:

• FedBizOpps.gov, Notice of Intent to Sole Source Oncotype Cancer Testing, Solicitation No: F3G4BA0337AW01